
Outcome Measures of New Technologies in Uveal Melanoma: Review from the European Vision Institute Special Interest Focus Group Meeting
Author(s) -
Beenakker Jan-Willem M.,
Brouwer Niels J.,
Chau Cindy,
Coupland Sarah E.,
Fiorentzis Miltiadis,
Heimann Heinrich,
Heufelder Jens,
Joussen Antonia M.,
Kiilgaard Jens F.,
Kivelä Tero T.,
Piperno-Neumann Sophie,
Rantala Elina S.,
Romanowska-Dixon Bozena,
Shields Carol L.,
Willerding Gregor D.,
Wheeler-Schilling Thomas,
Scholl Hendrik P.N.,
Jager Martine J.,
Damato Bertil E.
Publication year - 2022
Publication title -
ophthalmic research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.893
H-Index - 54
eISSN - 1423-0259
pISSN - 0030-3747
DOI - 10.1159/000524372
Subject(s) - review article
Uveal melanoma (UM) is the most common primary intraocular tumor in adults. New diagnostic procedures and basic science discoveries continue to change our patient management paradigms. A recent meeting of the European Vision Institute (EVI) special interest focus group was held on “Outcome Measures of New Technologies in Uveal Melanoma,” addressing the latest advances in UM, starting with genetic developments, then moving on to imaging and treatment of the primary tumor, as well as to investigating the most recent developments in treating metastases, and eventually taking care of the patient’s well-being. This review highlights the meeting’s presentations in the context of the published literature.